237 related articles for article (PubMed ID: 30672720)
1. No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Schoemakers RJ; van Kesteren C; van Rosmalen J; Eussen MLJM; Dieleman HG; Beex-Oosterhuis MM
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):192-196. PubMed ID: 30672720
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
3. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Pozzi M; Pisano S; Marano G; Carnovale C; Bravaccio C; Rafaniello C; Capuano A; Rossi F; Rizzo R; Bernardini R; Nobile M; Molteni M; Clementi E; Biganzoli E; Radice S
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):133-140. PubMed ID: 30452281
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
DeVane CL; Charles JM; Abramson RK; Williams JE; Carpenter LA; Raven S; Gwynette F; Stuck CA; Geesey ME; Bradley C; Donovan JL; Hall AG; Sherk ST; Powers NR; Spratt E; Kinsman A; Kruesi MJ; Bragg JE
Pharmacotherapy; 2019 Jun; 39(6):626-635. PubMed ID: 31063671
[TBL] [Abstract][Full Text] [Related]
5. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Wink LK; Early M; Schaefer T; Pottenger A; Horn P; McDougle CJ; Erickson CA
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):78-82. PubMed ID: 24564519
[TBL] [Abstract][Full Text] [Related]
6. Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder.
Yoon Y; Wink LK; Pedapati EV; Horn PS; Erickson CA
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):822-827. PubMed ID: 27389348
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
8. Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Mustafa S; Joober R; Iyer S; Shah J; Lepage M; Malla A
J Clin Psychiatry; 2019 Aug; 80(5):. PubMed ID: 31509359
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
11. Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders.
Houghton R; van den Bergh J; Law K; Liu Y; de Vries F
Autism Res; 2021 Aug; 14(8):1800-1814. PubMed ID: 34080319
[TBL] [Abstract][Full Text] [Related]
12. Iron homeostasis during risperidone treatment in children and adolescents.
Calarge CA; Ziegler EE; Del Castillo N; Aman M; McDougle CJ; Scahill L; McCracken JT; Arnold LE
J Clin Psychiatry; 2015 Nov; 76(11):1500-5. PubMed ID: 26301448
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
14. The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial.
Hermans RA; Ringeling LT; Liang K; Kloosterboer SM; de Winter BCM; Hillegers MHJ; Koch BCP; Dierckx B
BMC Psychiatry; 2022 Dec; 22(1):814. PubMed ID: 36539734
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
16. Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
Martin A; Landau J; Leebens P; Ulizio K; Cicchetti D; Scahill L; Leckman JF
J Child Adolesc Psychopharmacol; 2000; 10(4):259-68. PubMed ID: 11191686
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and pattern of weight gain in youths using antipsychotic drugs.
van der Esch CCL; Kloosterboer SM; van der Ende J; Reichart CG; Kouijzer MEJ; de Kroon MMJ; van Daalen E; Ester WA; Rieken R; Dieleman GC; Hillegers MHJ; van Gelder T; Koch BCP; Dierckx B
Eur Child Adolesc Psychiatry; 2021 Aug; 30(8):1263-1271. PubMed ID: 32839872
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Fortea A; Ilzarbe D; Espinosa L; Solerdelcoll M; de Castro C; Oriolo G; Sugranyes G; Baeza I
J Child Adolesc Psychopharmacol; 2018 May; 28(4):252-257. PubMed ID: 29381388
[TBL] [Abstract][Full Text] [Related]
19. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness.
Hermans RA; Sassen SDT; Kloosterboer SM; Reichart CG; Kouijzer MEJ; de Kroon MMJ; Bastiaansen D; van Altena D; van Schaik RHN; Nasserinejad K; Hillegers MHJ; Koch BCP; Dierckx B; de Winter BCM
Br J Clin Pharmacol; 2023 Oct; 89(10):3026-3036. PubMed ID: 37222228
[TBL] [Abstract][Full Text] [Related]
20. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
